Assessing sample representativeness in randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network

被引:49
|
作者
Susukida, Ryoko [1 ]
Crum, Rosa M. [1 ,2 ,3 ]
Stuart, Elizabeth A. [1 ]
Ebnesajjad, Cyrus [1 ]
Mojtabai, Ramin [1 ,3 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 North Broadway Room 897, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
关键词
Clinical trials; sample representativeness; substance use disorders; MOTIVATIONAL ENHANCEMENT THERAPY; BUPRENORPHINE-NALOXONE; SOCIOECONOMIC-STATUS; SUBSTANCE-ABUSE; GENERALIZABILITY; DEPENDENCE; INCENTIVES; PREDICTORS; EDUCATION; SELECTION;
D O I
10.1111/add.13327
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To compare the characteristics of individuals participating in randomized controlled trials (RCTs) of treatments of substance use disorder (SUD) with individuals receiving treatment in usual care settings, and to provide a summary quantitative measure of differences between characteristics of these two groups of individuals using propensity score methods. Design Analyses using data from RCT samples from the National Institute of Drug Abuse Clinical Trials Network (CTN) and target populations of patients drawn from the Treatment Episodes Data Set-Admissions (TEDS-A). Settings Multiple clinical trial sites and nation-wide usual SUD treatment settings in the United States. Participants A total of 3592 individuals from 10 CTN samples and 1 602 226 individuals selected from TEDS-A between 2001 and 2009. Measurements The propensity scores for enrolling in the RCTs were computed based on the following nine observable characteristics: sex, race/ethnicity, age, education, employment status, marital status, admission to treatment through criminal justice, intravenous drug use and the number of prior treatments. Findings The proportion of those with >= 12 years of education and the proportion of those who had full-time jobs were significantly higher among RCT samples than among target populations (in seven and nine trials, respectively, at P < 0.001). The pooled difference in the mean propensity scores between the RCTs and the target population was 1.54 standard deviations and was statistically significant at P < 0.001. Conclusions In the United States, individuals recruited into randomized controlled trials of substance use disorder treatments appear to be very different from individuals receiving treatment in usual care settings. Notably, RCT participants tend to have more years of education and a greater likelihood of full-time work compared with people receiving care in usual care settings.
引用
收藏
页码:1226 / 1234
页数:9
相关论文
共 50 条
  • [21] Achieving Cannabis Cessation - Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network
    McClure, Erin A.
    Sonne, Susan C.
    Winhusen, Theresa
    Carroll, Kathleen M.
    Ghitza, Udi E.
    McRae-Clark, Aimee L.
    Matthews, Abigail G.
    Sharma, Gaurav
    Van Veldhuisen, Paul
    Vandrey, Ryan G.
    Levin, Frances R.
    Weiss, Roger D.
    Lindblad, Robert
    Allen, Colleen
    Mooney, Larissa J.
    Haynes, Louise
    Brigham, Gregory S.
    Sparenborg, Steve
    Hasson, Albert L.
    Gray, Kevin M.
    CONTEMPORARY CLINICAL TRIALS, 2014, 39 (02) : 211 - 223
  • [22] Assessing abuse liability in clinical trials
    Brady, KT
    Lydiard, RB
    Brady, JV
    DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) : S87 - S95
  • [23] Partnerships and pathways of dissemination: The National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network
    Martino, Steve
    Brigham, Gregory S.
    Higgins, Christine
    Gallon, Steve
    Freese, Thomas E.
    Albright, Lonnetta M.
    Hulsey, Eric G.
    Krom, Laurie
    Storti, Susan A.
    Perl, Harold
    Nugent, Cathrine D.
    Pintello, Denise
    Condon, Timothy P.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2010, 38 (04) : S31 - S43
  • [24] Racial representativeness of cancer clinical trials sponsored by the National Cancer Institute compared to pharmaceutical companies
    Unger, Joseph M.
    Hershman, Dawn L.
    Osarogiagbon, Raymond U.
    Gothwal, Anirudh
    Anand, Seerat
    Dasari, Arvind
    Overnman, Michael
    Loree, Jonathan M.
    Raghav, Kanwal
    CANCER RESEARCH, 2020, 80 (16)
  • [25] National Institute on Drug Abuse Clinical Trials Network Meeting Report: Advancing Emergency Department Initiation of Buprenorphine for Opioid Use Disorder
    Cowan, Ethan
    Perrone, Jeanmarie
    Bernstein, Steven L.
    Coupet Jr, Edouard
    Fiellin, David A.
    Hawk, Kathryn
    Herring, Andrew
    Huntley, Kristen
    Mccormack, Ryan
    Venkatesh, Arjun
    D'Onofrio, Gail
    ANNALS OF EMERGENCY MEDICINE, 2023, 82 (03) : 326 - 335
  • [26] Nurse turnover in substance abuse treatment programs affiliated with the National Drug Abuse Treatment Clinical Trials Network
    Knudsen, Hannah K.
    Abraham, Amanda J.
    Roman, Paul M.
    Studts, Jamie L.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2011, 40 (03) : 307 - 312
  • [27] Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future
    Jalali, Ali
    Ryan, Danielle A.
    McCollister, Kathryn E.
    Marsch, Lisa A.
    Schackman, Bruce R.
    Murphy, Sean M.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 112 : 18 - 27
  • [28] A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid, detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network
    Ling, W
    Amass, L
    Shoptaw, S
    Annon, JJ
    Hillhouse, M
    Babcock, D
    Brigham, G
    Harrer, J
    Reid, M
    Muir, J
    Buchan, B
    Orr, D
    Woody, G
    Krejci, J
    Ziedonis, D
    ADDICTION, 2005, 100 (08) : 1090 - 1100
  • [29] THE INSTITUTE OF MEDICINE, THE NATIONAL CANCER INSTITUTE, AND CLINICAL TRIALS
    Cox, James D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (05): : 1285 - 1286
  • [30] Randomized controlled clinical trials
    Cole, CH
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2003, 39 (02) : 161 - 161